Mirtazapin Dura (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapin Dura, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for oral use. It is prescribed for major depressive disorder in adult patients. GNH USA supplies Mirtazapin Dura as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine acts on depressive disorders and related mood conditions. - Major depressive disorder: reduces depressive symptoms and improves mood in adults. - Treatment‑resistant depression: provides an alternative mechanism when first‑line agents are insufficient. - Depression with insomnia or loss of appetite: helps improve sleep quality and stimulates appetite.

Mirtazapin Dura may cause a range of adverse reactions.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Suicidal thoughts, especially early in treatment - Serotonin syndrome when combined with other serotonergic agents - Severe hypersensitivity reactions - Cardiac arrhythmias

When prescribing Mirtazapin Dura, clinicians should consider several safety measures. - Dose adjustment in hepatic impairment: reduce dose as needed. - Monitor weight and metabolic parameters: due to potential appetite increase. - Assess for suicidal ideation: especially at treatment initiation. - Caution in elderly: higher risk of sedation and falls. - Avoid abrupt discontinuation: taper dose to prevent withdrawal symptoms. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Mirtazapin Dura can interact with several drug classes.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis. - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may raise mirtazapine plasma levels. - CNS depressants (e.g., alcohol, benzodiazepines): enhanced sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., carbamazepine, phenytoin): may reduce efficacy. - Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): increased risk of serotonin syndrome. - Anticholinergic drugs: additive anticholinergic effects such as dry mouth and constipation.